Multi-Epitope Her2 Peptide Vaccine Tpiv100
Breast Adenocarcinoma
Academic and Community Cancer Research UnitedvaccinePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
25 Active assets in the Breast Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 | BB |
TRASTUZUMAB Academic and Community Cancer Research United | Phase 3 | BB |
Inno-206 Virginia Commonwealth University | Phase 3 | BB |
Letrozole Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 4 | BB |
Carboplatin Genmab | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Multi-Epitope Her2 Peptide Vaccine Tpiv100 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →